Optimizing Endocrinology Peer-to-Peer Scheduling with Automation

Klivira streamlines endocrinology peer-to-peer scheduling, transforming a time-consuming manual process into an efficient, automated workflow that reduces clinician burden and accelerates access to critical therapies.

For revenue cycle directors and prior authorization coordinators in endocrinology, managing peer-to-peer (P2P) reviews for complex conditions like diabetes and growth hormone deficiencies is a significant bottleneck. The high volume of denials for GLP-1 agonists, CGMs, and insulin pumps, often due to stringent payer criteria, necessitates frequent P2P interventions. Manual scheduling and documentation preparation drain valuable clinical and administrative resources, delaying patient care.

The Unique Challenges of Endocrinology P2P Scheduling

Endocrinology practices face substantial P2P volumes driven by specific high-cost drug categories and devices. Denials for GLP-1 receptor agonists (semaglutide, tirzepatide), continuous glucose monitors (CGMs), insulin pumps, and growth hormone therapy frequently trigger P2P reviews. These often stem from payer-specific coverage gaps for obesity indications, strict step-therapy requirements, or criteria for CGM coverage in non-insulin-requiring T2D, making efficient P2P scheduling critical for patient access.

Common Endocrinology PA Triggers Requiring P2P Review

GLP-1 receptor agonists (Ozempic, Mounjaro, Zepbound) for T2D and obesity, often due to strict BMI criteria or step-therapy adherence.
Continuous Glucose Monitoring (Dexcom G7, FreeStyle Libre 3) denials for T2D patients not meeting insulin-requiring status.
Insulin pumps and tubeless systems (Tandem t:slim X2, Omnipod 5) requiring documentation of prior MDI trials or patient adherence.
Growth hormone therapy (somatropin biosimilars) denials based on diagnostic documentation or IGF-1 levels.
SGLT2 inhibitors (Jardiance, Farxiga) for heart failure or CKD indications where specific ejection fraction or eGFR thresholds are challenged.

Klivira's Automated Peer-to-Peer Scheduling for Endocrinology

Klivira's platform automates the entire peer-to-peer scheduling workflow, specifically designed to address the high-volume, complex denials common in endocrinology. Our denial-router triages P2P-eligible cases, initiates payer-side window discovery, and integrates directly with ordering clinician calendars via FHIR Appointment resource or customer-configured calendar systems. This eliminates the manual three-way scheduling friction, ensuring optimal windows are secured efficiently.

Automated Documentation and Clinical Guideline Adherence

For endocrinology P2P calls, Klivira automates the assembly of comprehensive pre-call packets. This includes pulling clinical notes, prior-line therapy history, lab/imaging results, and relevant peer-reviewed literature via FHIR. The system integrates with clinical guideline frameworks like ADA Standards of Care, AACE Clinical Practice Guidelines, and ATA Guidelines to ensure clinicians are fully prepared with evidence-grounded talking points, particularly crucial for nuanced GLP-1 or growth hormone indications.

Seamless EMR and Payer Touchpoints for Endocrinology Workflows

Klivira integrates deeply with EMRs to support endocrinology P2P scheduling. Utilizing FHIR Appointment for calendar synchronization, FHIR DocumentReference for automated pre-call packet assembly, and FHIR Communication for P2P-related notifications, our platform ensures all relevant data is accessible and outcomes are captured. Post-call, Klivira captures the outcome via a structured form and writes it back to the EMR, triggering downstream workflows for approvals or further appeals.

Addressing Clinician Burden and Improving Outcomes

The AMA prior authorization physician survey highlights P2P reviews as a significant contributor to clinician burnout. Klivira's automation reduces this burden by eliminating manual scheduling, preparing comprehensive documentation, and providing automated reminders. By streamlining the process, endocrinologists can focus on clinical discussions, improving the likelihood of overturning denials for critical therapies like GLP-1s, CGMs, and insulin pumps, ultimately enhancing patient care.

Frequently asked questions

How does Klivira handle P2P scheduling for GLP-1s with variable obesity coverage?

Klivira's denial-router identifies P2P-eligible denials for GLP-1s, including those challenged on obesity indications. The system then automates the scheduling process and prepares a pre-call packet with documentation supporting the specific indication, such as BMI criteria, prior weight-management interventions, and lifestyle modification records, aligning with payer-specific coverage requirements.

What EMR integrations support endocrinology P2P scheduling?

Klivira integrates with EMRs using SMART on FHIR standards, leveraging FHIR Appointment resources for clinician calendar synchronization. This allows for seamless discovery of available P2P slots and automated booking, reducing manual coordination efforts for endocrinology practices.

Can Klivira automate pre-call documentation for CGM re-authorizations?

Yes, for CGM re-authorizations requiring P2P, Klivira automatically assembles a pre-call packet. This includes pulling patient adherence documentation, diabetes diagnosis, insulin-requiring status, and hypoglycemia history from the EMR, ensuring the endocrinologist has all necessary information for the review.

How does Klivira address the clinician time burden for endocrinology P2Ps?

Klivira significantly reduces clinician burden by automating the scheduling of P2P calls, integrating directly with their calendars. It also prepares comprehensive pre-call documentation packets, eliminating the need for clinicians or staff to manually gather information, allowing endocrinologists to focus solely on the clinical discussion during the call.

Does Klivira provide analytics on endocrinology P2P success rates?

Yes, Klivira tracks P2P outcomes and provides analytics on success patterns by denial reason, payer, and clinician. This feedback loop helps endocrinology practices identify common denial trends and refine upstream prior authorization submission strategies to improve initial approval rates and reduce the need for P2P.